Rivus Pharmaceuticals Unveils Promising Results from Phase 2a HuMAIN Trial for Obesity-Related Heart Failure

Rivus Pharmaceuticals Unveils Promising Results from Phase 2a HuMAIN Trial for Obesity-Related Heart Failure



Rivus Pharmaceuticals, a clinical-stage biopharmaceutical company, has recently made headlines with the publication of the Phase 2a HuMAIN trial results for their investigational drug, HU6. Featured in JAMA Cardiology, the study focuses on patients suffering from obesity-related heart failure with preserved ejection fraction (HFpEF).

Key Findings


The HuMAIN trial aimed to evaluate the efficacy and safety of HU6 over a span of 19 weeks. Participants taking HU6 showed significant weight loss compared to those receiving a placebo. The data revealed that the average participant had a reduction of 6.8 pounds, while the placebo group lost only 0.5 pounds (p=0.0026). Notably, these results were attributed to substantial decreases in fat mass and visceral fat, all achieved while preserving lean muscle mass.

Ambarish Pandey, M.D., a cardiologist and lead author of the study, expressed optimism regarding HU6’s potential to significantly impact visceral fat, which is closely linked to the progression of HFpEF. This is particularly meaningful as HFpEF affects a growing population, and effective treatment options have been limited.

The Science Behind HU6


HU6 belongs to a new class of investigational therapies known as Controlled Metabolic Accelerators (CMAs). This oral medication works by selectively enhancing metabolic rates that lead to fat loss while keeping lean mass intact. The study demonstrated not only weight reduction but also marked improvements in critical cardiovascular metrics and metabolic health.

Among the important secondary endpoints evaluated were improvements in left ventricular systolic function and reductions in both systolic and diastolic blood pressure, indicating that HU6 could be beneficial not just for weight management but for overall heart health as well.

Safety Profile and Overall Tolerability


The safety profile of HU6 has shown consistency with prior studies. Most participants rated its tolerability positively, with only a few experiencing serious adverse events not linked to HU6. This is particularly noteworthy given the elderly and unhealthy demographics of study participants who typically have multiple comorbidities and often take numerous medications.

“It’s evident that the study results, although from a small sample and short duration, pave the way for further investigation into HU6 as a potential disease-modifying treatment for HFpEF,” stated Jayson Dallas, M.D., CEO of Rivus Pharmaceuticals.

Topics Other)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.